ONC201 Publications

onc201

Epidermal growth factor receptor as a molecular determinant of glioblastoma response to dopamine receptor D2 inhibitors

Neuro Oncol. 2021 PMID: 32830856

He Y, Li J, Koga T, et al.

onc201

A Bayesian machine learning approach for drug target identification using diverse data types

Nat Commun. 2019 PMID: 31745082

Madhukar NS, Khade PK, Huang L, et al.

onc201

Biological activity of weekly ONC201 in adult recurrent glioblastoma patients

Neuro Oncol. 2020 PMID: 31702782

Arrillaga-Romany I, Odia Y, Prabhu VV, et al.

onc201

Pediatric and adult H3 K27M-mutant diffuse midline glioma treated with the selective DRD2 antagonist ONC201

J Neurooncol. 2019 PMID: 31456142

Chi AS, Tarapore RS, Hall MD, et al.

onc201

Safety and enhanced immunostimulatory activity of the DRD2 antagonist ONC201 in advanced solid tumor patients with weekly oral administration

J Immunother Cancer. 2019 PMID: 31118108

Stein MN, Malhotra J, Tarapore RS, et al.

onc201

Dopamine receptor D5 is a modulator of tumor response to dopamine receptor D2 antagonism

Clin Cancer Res. 2019 PMID: 30559168

Prabhu VV, Madhukar NS, Gilvary C, et al.

onc201

Dose intensification of TRAIL-inducing ONC201 inhibits metastasis and promotes intratumoral NK cell recruitment

J Clin Invest. 2018 PMID: 29533922

Wagner J, Kline CL, Zhou L, et al.

onc201

A phase 2 study of the first imipridone ONC201, a selective DRD2 antagonist for oncology, administered every three weeks in recurrent glioblastoma. Oncotarget

Oncotarget. 2017 PMID: 29108308

Arrillaga-Romany I, Chi AS, Allen JE, et al.

onc201

First-in-Human clinical trial of oral ONC201 in patients with refractory solid tumors

Clin Cancer Res. 2017 PMID: 28331050

Stein MN, Bertino JR, Kaufman HL, et al.

onc201

ATF4 induction through an atypical integrated stress response to ONC201 triggers p53-independent apoptosis in hematological malignancies

Sci Signal. 2016 PMID: 26884599

Ishizawa J, Kojima K, Chachad D, et al.